Absci Stock Jumps

AMD invests $20 million in AI drug research at Vancouver-based Absci
Chip designer AMD said Wednesday that it will invest $20 million in Absci, the Vancouver company that aims to use artificial intelligence to develop new drug therapies. Absci hopes artificial intelligence will enable it to move faster to develop protein-based medicines called biologics,
Absci Stock Jumps As AMD Invests $20M To Boost AI Drug Discovery
AI drug creation company Absci Corporation (NASDAQ:ABSI) shares are trading higher in premarket on Wednesday after the company entered into a strategic collaboration with Advanced Micro Devices Inc (NASDAQ:AMD) to enhance its AI drug discovery capabilities.
AMD invests $20M in AI-powered drug discovery company Absci
Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop new hardware and software optimized for the healthcare sector. The effort will place particular emphasis on developing technologies that can advance drug discovery.
AMD Invests in Drug-Discovery Company Absci in Push to Sell AI Chips
The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other industries.
Absci Announces Strategic Collaboration With AMD To Advance AI-Driven Drug Discovery
Absci Corporation (ABSI), a Washington-based biotechnology company, Wednesday has announced a strategic collaboration with AMD to
AMD to invest $20m in Absci to boost AI drug discovery tech
AMD's technology will also be used to boost Absci's drug discovery workload, including the company's de novo antibody design models.
AMD is going head-to-head with Nvidia in AI-backed drug discovery with new deal
Chip maker AMD is investing $20 million in AI drug startup Absci, which will use AMD chips and software for drug development.
Absci stock soars on AMD partnership and investment
Investing.com -- Shares of Absci Corporation (NASDAQ: ABSI) soared 50% following the announcement of a strategic collaboration and a $20 million investment from AMD (NASDAQ: AMD ). The partnership aims to enhance Absci's AI-driven drug discovery capabilities using AMD's Instinct accelerators and ROCm software.
Absci (NASDAQ:ABSI) Given New $5.00 Price Target at KeyCorp
Absci (NASDAQ:ABSI – Free Report) had its price objective cut by KeyCorp from $6.00 to $5.00 in a research note released on Wednesday,Benzinga reports. They currently have an overweight rating on the ...
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics ...
GEN13h
StockWatch: Will Expanding to Life Sciences Reverse AMD’s Stock Decline?
Investors sell off AMD shares despite the company's pivot to life sciences AI, following a rating downgrade by HSBC that followed a six-month decline in the stock price.
AMD Shares Slide as HSBC Downgrades Stock Over Nvidia Concerns; Absci Collaboration Announced
Following HSBC downgrading of the semiconductor company's stock, Advanced Micro Devices ( AMD, Financials) shares fell over 5 ...
Cathie Wood’s ARK Investment buys 609K shares of Absci today
EST Cathie Wood’s ARK Investment buys 609K shares of Absci (ABSI) todayStay Ahead of the Market:Discover outperforming stocks and invest ...
Absci rises after report on $20M investment by Advanced Micro Devices
Absci (NASDAQ:ABSI) was rising after a media report about the semiconductor company Advanced Micro Devices (NASDAQ:AMD) ...